Sino Biopharmaceutical reports stable share capital for September

As of September 30, 2025, Sino Biopharmaceutical Limited maintained its authorized share capital at HK$750,000,000, comprising 30,000,000,000 ordinary shares with a par value of HK$0.025 each. There were no increases or decreases in the authorized share capital during the reporting month.

The company's issued share capital also remained consistent, with 18,760,717,230 ordinary shares outstanding at the end of September. No new shares were issued, nor were any treasury shares transferred during the month.

Furthermore, Sino Biopharmaceutical reported zero movements in share options. A share option scheme adopted at the annual general meeting on June 15, 2023, currently has no outstanding options, and no new shares were issued pursuant to the scheme in September 2025.